{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:20:01Z","timestamp":1794345601239,"version":"4.9.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11864-025-01365-x","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T02:53:44Z","timestamp":1760669624000},"page":"1061-1077","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Second-Line Treatment in cholangiocarcinoma - Current State of the Art and Future Perspectives"],"prefix":"10.1007","volume":"26","author":[{"given":"Micha\u0142","family":"Siwek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Chmiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Grabowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Gr\u0105t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leszek","family":"Kraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"issue":"5","key":"1365_CR1","first-page":"43","volume":"107","author":"S Kidanemariam","year":"2024","unstructured":"Kidanemariam S, Gu J, Yoon JH, Challapalli JV, Fruh V, Sax AJ. Cholangiocarcinoma: epidemiology and Imaging-Based review. Rhode Island Med J (2013). 2024;107(5):43\u20138.","journal-title":"Rhode Island Med J (2013)"},{"key":"1365_CR2","doi-asserted-by":"crossref","unstructured":"Biliary tract cancer. ESMO clinical practice guideline for diagnosis, treatment and follow-up. Vogel. A. Ann Oncol, 34, Issue 2, 127\u201340.","DOI":"10.1016\/j.annonc.2022.10.506"},{"issue":"6","key":"1365_CR3","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.jhep.2022.07.022","volume":"77","author":"M Vithayathil","year":"2022","unstructured":"Vithayathil M, Khan SA. Current epidemiology of cholangiocarcinoma in Western countries. J Hepatol. 2022;77(6):1690\u20138. https:\/\/doi.org\/10.1016\/j.jhep.2022.07.022.","journal-title":"J Hepatol"},{"issue":"3","key":"1365_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.32074\/1591-951X-252","volume":"113","author":"S Sarcognato","year":"2021","unstructured":"Sarcognato S, Sacchi D, Fassan M, et al. Cholangiocarcinoma Pathologica. 2021;113(3):158\u201369. https:\/\/doi.org\/10.32074\/1591-951X-252.","journal-title":"Cholangiocarcinoma Pathologica"},{"key":"1365_CR5","doi-asserted-by":"publisher","first-page":"101951","DOI":"10.1016\/j.mcp.2024.101951","volume":"73","author":"M Capuozzo","year":"2024","unstructured":"Capuozzo M, Santorsola M, Ferrara F, Cinque C, Farace S, Patrone R, Granata V, Zovi A, Nasti G, Ottaiano A. Intrahepatic cholangiocarcinoma biomarkers: towards early detection and personalized Pharmacological treatments. Mol Cell Probes. 2024;73:101951. https:\/\/doi.org\/10.1016\/j.mcp.2024.101951.","journal-title":"Mol Cell Probes"},{"issue":"9","key":"1365_CR6","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.3748\/wjg.v30.i9.1018","volume":"30","author":"FS Dar","year":"2024","unstructured":"Dar FS, Abbas Z, Ahmed I, et al. National guidelines for the diagnosis and treatment of hilar cholangiocarcinoma. World J Gastroenterol. 2024;30(9):1018\u201342. https:\/\/doi.org\/10.3748\/wjg.v30.i9.1018.","journal-title":"World J Gastroenterol"},{"issue":"18","key":"1365_CR7","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.2217\/fon-2021-1302","volume":"18","author":"ZS Khankhel","year":"2022","unstructured":"Khankhel ZS, Goring S, Bobiak S, et al. Second-line treatments in advanced biliary tract cancer: systematic literature review of efficacy, effectiveness and safety. Future Oncol. 2022;18(18):2321\u201338. https:\/\/doi.org\/10.2217\/fon-2021-1302.","journal-title":"Future Oncol"},{"issue":"14","key":"1365_CR8","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381. https:\/\/doi.org\/10.1056\/NEJMoa0908721.","journal-title":"N Engl J Med"},{"issue":"4","key":"1365_CR9","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","volume":"103","author":"T Okusaka","year":"2010","unstructured":"Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103(4):469\u201374. https:\/\/doi.org\/10.1038\/sj.bjc.6605779.","journal-title":"Br J Cancer"},{"key":"1365_CR10","doi-asserted-by":"crossref","unstructured":"78P Updated overall. Survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+\u2009GC) in patients (pts) with advanced biliary tract cancer (BTC). Oh, D-Y. Annals of Oncology, Volume 33, S1462 - S1463.","DOI":"10.1016\/j.annonc.2022.10.114"},{"issue":"11","key":"1365_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/life13112170","volume":"13","author":"I Garajov\u00e1","year":"2023","unstructured":"Garajov\u00e1 I, Gelsomino F, Salati M, et al. Second-line chemotherapy for intrahepatic cholangiocarcinomas: what is the real gain? Life. 2023;13(11):2170. https:\/\/doi.org\/10.3390\/life13112170.","journal-title":"Life"},{"key":"1365_CR12","doi-asserted-by":"publisher","unstructured":"Kelley RK, Ueno M, Yoo C et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet. 2023;402(10406):964. doi: 10.1016\/S0140-6736(23)01904-9.] [published correction appears in Lancet. 2024;403(10432):1140. doi: 10.1016\/S0140-6736(24)00545-2.]. Lancet. 2023;401(10391):1853\u20131865. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4","DOI":"10.1016\/S0140-6736(23)00727-4"},{"issue":"3","key":"1365_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100505","volume":"7","author":"N Normanno","year":"2022","unstructured":"Normanno N, Martinelli E, Melisi D, et al. Role of molecular genetics in the clinical management of cholangiocarcinoma. ESMO Open. 2022;7(3):100505. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100505.","journal-title":"ESMO Open"},{"issue":"2","key":"1365_CR14","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3322\/caac.21759","volume":"73","author":"D Moris","year":"2023","unstructured":"Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin. 2023;73(2):198\u2013222. https:\/\/doi.org\/10.3322\/caac.21759.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1365_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3390\/curroncol32010044","volume":"32","author":"A Bray","year":"2025","unstructured":"Bray A, Sahai VIDH, Mutant Cholangiocarcinoma. Pathogenesis, Management, and future therapies. Curr Oncol. 2025;32(1):44. https:\/\/doi.org\/10.3390\/curroncol32010044. Published 2025 Jan 17.","journal-title":"Curr Oncol"},{"issue":"11","key":"1365_CR16","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","volume":"7","author":"AX Zhu","year":"2021","unstructured":"Zhu AX, Macarulla T, Javle MM, et al. Final overall survival efficacy results of Ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol. 2021;7(11):1669\u201377. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3836.","journal-title":"JAMA Oncol"},{"issue":"9","key":"1365_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16091690","volume":"16","author":"P Heumann","year":"2024","unstructured":"Heumann P, Albert A, G\u00fclow K, T\u00fcmen D, M\u00fcller M, Kandulski A. Current and future therapeutic targets for directed molecular therapies in cholangiocarcinoma. Cancers (Basel). 2024;16(9):1690. https:\/\/doi.org\/10.3390\/cancers16091690.","journal-title":"Cancers (Basel)"},{"key":"1365_CR18","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","volume":"29","author":"V Subbiah","year":"2023","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib plus Trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat Med. 2023;29:1103\u201312. https:\/\/doi.org\/10.1038\/s41591-023-02321-8.","journal-title":"Nat Med"},{"issue":"1","key":"1365_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1\u201310. https:\/\/doi.org\/10.1200\/JCO.19.02105.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1365_CR20","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","volume":"22","author":"M Javle","year":"2021","unstructured":"Javle M, Borad MJ, Azad NS, et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021;22(9):1290\u2013300. https:\/\/doi.org\/10.1016\/S1470-2045(21)00336-3.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1365_CR21","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2310196","volume":"56","author":"Y Li","year":"2024","unstructured":"Li Y, Yu J, Zhang Y, Peng C, Song Y, Liu S. Advances in targeted therapy of cholangiocarcinoma. Ann Med. 2024;56(1):2310196. https:\/\/doi.org\/10.1080\/07853890.2024.2310196.","journal-title":"Ann Med"},{"issue":"3","key":"1365_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/wdev.176","volume":"4","author":"DM Ornitz","year":"2015","unstructured":"Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. WIREs Dev Biol. 2015;4(3):215\u201366. https:\/\/doi.org\/10.1002\/wdev.176.","journal-title":"WIREs Dev Biol"},{"issue":"5","key":"1365_CR23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(23)00642-3","volume":"21","author":"GK Abou-Alfa","year":"2024","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study [published correction appears in Lancet Oncol. Lancet Oncol. 2024;21(5):671\u201384. https:\/\/doi.org\/10.1016\/S1470-2045(23)00642-3.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1365_CR24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","volume":"388","author":"L Goyal","year":"2023","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388(3):228\u201339. https:\/\/doi.org\/10.1056\/NEJMoa2206834.","journal-title":"N Engl J Med"},{"key":"1365_CR25","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1200\/JCO.2022.40.16_suppl.4009","volume":"40","author":"L Goyal","year":"2022","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A, et al. Updated results of the FOENIX-CCA2 trial: efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions\/rearrangements. J Clin Oncol. 2022;40:4009\u20134009. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.4009.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1365_CR26","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","volume":"6","author":"M Javle","year":"2021","unstructured":"Javle M, Roychowdhury S, Kelley RK, et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021;6(10):803\u201315. https:\/\/doi.org\/10.1016\/S2468-1253(21)00196-5.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"1365_CR27","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca A, Palmer DH, Wasan HS, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22(5):690\u2013701. https:\/\/doi.org\/10.1016\/S1470-2045(21)00027-9.","journal-title":"Lancet Oncol"},{"key":"1365_CR28","doi-asserted-by":"crossref","unstructured":"ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer. Vogel, A. ESMO Open, Volume 10, Issue 1, 104003.","DOI":"10.1016\/j.esmoop.2024.104003"},{"issue":"10","key":"1365_CR29","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","volume":"23","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and safety of Selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial. Lancet Oncol. 2022;23(10):1261\u201373. https:\/\/doi.org\/10.1016\/S1470-2045(22)00541-1.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1365_CR30","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1001\/jamaoncol.2023.0016","volume":"9","author":"J Hyung","year":"2023","unstructured":"Hyung J, Kim I, Kim KP, et al. Treatment with liposomal irinotecan plus fluorouracil and leucovorin for patients with previously treated metastatic biliary tract cancer: the phase 2b NIFTY randomized clinical trial. JAMA Oncol. 2023;9(5):692\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2023.0016.","journal-title":"JAMA Oncol"},{"key":"1365_CR31","doi-asserted-by":"crossref","first-page":"S563","DOI":"10.1016\/j.annonc.2022.03.009","volume":"33","author":"A Vogel","year":"2022","unstructured":"Vogel A, et al. 53MO nal-IRI and 5-FU\/LV compared to 5-FU\/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC \u2013 AIO-HEP-0116). Ann Oncol. 2022;33:S563\u20134.","journal-title":"Ann Oncol"},{"key":"1365_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102447","volume":"69","author":"T Shimoi","year":"2024","unstructured":"Shimoi T, Sunami K, Tahara M, et al. Dabrafenib and trametinib administration in patients with BRAFV600E\/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial. EClinMed. 2024;69:102447. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102447.","journal-title":"EClinMed"},{"issue":"20","key":"1365_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14205074","volume":"14","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Esmail A, Mazzaferro V, Abdelrahim M. Newest therapies for cholangiocarcinoma: an updated overview of approved treatments with transplant oncology vision. Cancers (Basel). 2022;14(20):5074. https:\/\/doi.org\/10.3390\/cancers14205074.","journal-title":"Cancers (Basel)"},{"key":"1365_CR34","unstructured":"Harding J, JAbou-Alfa G et al. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. The Lancet Oncology, Volume 24, Issue 7, 772\u201382."},{"key":"1365_CR35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024;42:47\u201358.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1365_CR36","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1158\/1535-7163.MCT-16-0589","volume":"16","author":"TPS Perera","year":"2017","unstructured":"Perera TPS, Jovcheva E, Mevellec L, et al. Discovery and pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small-molecule FGFR family inhibitor. Mol Cancer Ther. 2017;16(6):1010\u201320. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0589.","journal-title":"Mol Cancer Ther"},{"key":"1365_CR37","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1200\/JCO.2019.37.15_suppl.4117","volume":"37","author":"JO Park","year":"2019","unstructured":"Park JO, Feng Y-H, Chen Y-Y, et al. Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations. J Clin Oncol. 2019;37:4117. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.4117.","journal-title":"J Clin Oncol"},{"key":"1365_CR38","doi-asserted-by":"publisher","first-page":"S567","DOI":"10.1016\/j.annonc.2022.07.087","volume":"33","author":"M Borad","year":"2022","unstructured":"Borad M, et al. 59P efficacy of Derazantinib in intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions, mutations or amplifications. Ann Oncol. 2022;33:S567\u20138.","journal-title":"Ann Oncol"},{"issue":"4","key":"1365_CR39","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364. https:\/\/doi.org\/10.1038\/nrc3239.","journal-title":"Nat Rev Cancer"},{"key":"1365_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-69366-4","volume":"10","author":"S Ahn","year":"2020","unstructured":"Ahn S, Lee J, Shin DW, et al. High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer. Sci Rep. 2020;10:12348. https:\/\/doi.org\/10.1038\/s41598-020-69366-4.","journal-title":"Sci Rep"},{"issue":"2","key":"1365_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020820","volume":"23","author":"D Ciardiello","year":"2022","unstructured":"Ciardiello D, Maiorano BA, Parente P, et al. Immunotherapy for biliary tract cancer in the era of precision medicine: current knowledge and future perspectives. Int J Mol Sci. 2022;23(2):820. https:\/\/doi.org\/10.3390\/ijms23020820.","journal-title":"Int J Mol Sci"},{"key":"1365_CR42","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1002\/ijc.33751","volume":"149","author":"X Chen","year":"2021","unstructured":"Chen X, Qin S, Gu S, et al. Camrelizumab plus oxaliplatin- based chemotherapy as first-line therapy for advanced biliary tract cancer: a multicenter, phase 2 trial. Int J Cancer. 2021;149:1944\u201354.","journal-title":"Int J Cancer"},{"issue":"Suppl. S15","key":"1365_CR43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e16170","volume":"39","author":"W Li","year":"2021","unstructured":"Li W, Yu Y, Xu X, et al. Toripalimab with chemotherapy as first-line treatment for advanced biliary tract tumors: update analytic results of an open-label phase II clinical study (JS001-ZS BC001). J Clin Oncol. 2021;39(Suppl. S15):e16170.","journal-title":"J Clin Oncol"},{"issue":"Suppl. S15","key":"1365_CR44","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1200\/JCO.2020.38.15_suppl.4520","volume":"38","author":"D-Y Oh","year":"2020","unstructured":"Oh D-Y, Lee K-H, Lee D-W, et al. Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D)\u2009\u00b1\u2009tremelimumab (T) and gemcitabine\/cisplatin (GemCis) in chemo-na\u00efve advance biliary tract cancer (aBTC). J Clin Oncol. 2020;38(Suppl. S15):4520.","journal-title":"J Clin Oncol"},{"issue":"Suppl. S4","key":"1365_CR45","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1200\/JCO.2019.37.4_suppl.387","volume":"37","author":"T Ioka","year":"2019","unstructured":"Ioka T, Ueno M, Oh D-Y, et al. Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC). J Clin Oncol. 2019;37(Suppl. S4):387.","journal-title":"J Clin Oncol"},{"issue":"Suppl. S15","key":"1365_CR46","doi-asserted-by":"publisher","first-page":"4588","DOI":"10.1200\/JCO.2020.38.15_suppl.4588","volume":"38","author":"O Klein","year":"2020","unstructured":"Klein O, Kee D, Nagrial A, et al. Combination immunotherapy with ipilimumab and nivolumab in patients with advanced biliary tract cancers. J Clin Oncol. 2020;38(Suppl. S15):4588.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1365_CR47","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.suronc.2016.12.009","volume":"26","author":"AA Rahnemai-Azar","year":"2017","unstructured":"Rahnemai-Azar AA, Weisbrod A, Dillhoff M. Intrahepatic cholangiocarcinoma: molecular markers for diagnosis and prognosis. Surg Oncol. 2017;26(2):125\u201337. https:\/\/doi.org\/10.1016\/j.suronc.2016.12.009.","journal-title":"Surg Oncol"},{"issue":"2","key":"1365_CR48","doi-asserted-by":"publisher","first-page":"67","DOI":"10.21037\/hbsn.2016.12.10","volume":"6","author":"KF \u0301abrega-Foster","year":"2017","unstructured":"\u0301abrega-Foster KF, Ghasabeh MA, Pawlik TM, Kamel IR. Multimodality imaging of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017;6(2):67\u201378. https:\/\/doi.org\/10.21037\/hbsn.2016.12.10.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"6","key":"1365_CR49","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1007\/s00261023-03890-5","volume":"48","author":"LH Liu","year":"2023","unstructured":"Liu LH, Wang ML, Jiang F. Distinct radiological features of lymphoepithelioma-like intrahepatic cholangiocarcinoma: comparison with classical intrahepatic cholangiocarcinoma. Abdom Radiol (NY). 2023;48(6):2038\u201348. https:\/\/doi.org\/10.1007\/s00261023-03890-5.","journal-title":"Abdom Radiol (NY)"},{"issue":"2","key":"1365_CR50","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/jhbp.156","volume":"22","author":"H Haga","year":"2015","unstructured":"Haga H, Patel T. Molecular diagnosis of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2015;22(2):114\u201323. https:\/\/doi.org\/10.1002\/jhbp.156.","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"8","key":"1365_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082039","volume":"12","author":"S Chakrabarti","year":"2020","unstructured":"Chakrabarti S, Kamgar M, Mahipal A. Targeted therapies in advanced biliary tract cancer: an evolving paradigm. Cancers. 2020;12(8):2039. https:\/\/doi.org\/10.3390\/cancers12082039.","journal-title":"Cancers"},{"issue":"11","key":"1365_CR52","first-page":"6663","volume":"34","author":"F Lumachi","year":"2014","unstructured":"Lumachi F, Lo Re G, Tozzoli R. Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19\u2009\u2013\u20099, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: a preliminary case-control study. Anticancer Res. 2014;34(11):6663\u20137.","journal-title":"Anticancer Res"},{"issue":"10","key":"1365_CR53","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.7150\/thno.56539","volume":"11","author":"J Lin","year":"2021","unstructured":"Lin J, Cao Y, Yang X, et al. Mutational spectrum and precision oncology for biliary tract carcinoma. Theranostics. 2021;11(10):4585\u201398. https:\/\/doi.org\/10.7150\/thno.56539.","journal-title":"Theranostics"},{"issue":"1","key":"1365_CR54","doi-asserted-by":"publisher","DOI":"10.1515\/biol-2022-0652","volume":"18","author":"J Peng","year":"2023","unstructured":"Peng J, Fang S, Li M, et al. Genetic alterations of KRAS and TP53 in intrahepatic cholangiocarcinoma associated with poor prognosis. Open Life Sci. 2023;18(1):20220652. https:\/\/doi.org\/10.1515\/biol-2022-0652.","journal-title":"Open Life Sci"},{"issue":"3","key":"1365_CR55","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jhep.2017.03.026","volume":"67","author":"S Rizvi","year":"2017","unstructured":"Rizvi S, Gores GJ. Emerging molecular therapeutic targets for cholangiocarcinoma. J Hepatol. 2017;67(3):632\u201344. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.026.","journal-title":"J Hepatol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01365-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01365-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01365-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:46:10Z","timestamp":1763642770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01365-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":55,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1365"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01365-x","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}